Carlson Investments: Bioaccure Launches Next-Gen On-Site PCR for Food, Farming and Veterinary

WARSAW, Poland - Sept. 5, 2025 - PRLog -- Carlson Investments SE is pleased to highlight the progress of its portfolio company Bioaccure, which has developed a compact, next-generation molecular diagnostics platform that enables real-time PCR testing directly at the point of sample collection.

Unlike traditional PCR systems, which require complex laboratory infrastructure and cold-chain logistics, Bioaccure's patented PCR.smart analyzer integrates sample preparation, DNA isolation, amplification, detection, and interpretation into a single, portable device. The platform delivers lab-quality results in under 90 minutes, making advanced diagnostics accessible across diverse environments.

With applications spanning plant and animal health, food safety, water quality, and veterinary diagnostics, Bioaccure empowers farmers, food producers, distributors, veterinarians, and inspectors to identify pathogens with unmatched speed, sensitivity, and cost efficiency. Current ready-to-use assays include detection of Salmonella spp., Campylobacter spp., Listeria monocytogenes, E. coli, and Fusarium species, with an expanding pipeline tailored to industry needs.

Key Features of Bioaccure

• Portable, compact platform enabling on-site testing
• End-to-end workflow from DNA isolation to result interpretation in  under 90 minutes
• Supports qPCR, PCR, and LAMP assays
• No need for cold storage or sample transport
• Detects bacteria, viruses, fungi, parasites, and genetic mutations
• Designed for non-specialist users with simple, intuitive operation
  
  

About Bioaccure
Bioaccure is a molecular diagnostics innovator specializing in real-time PCR platforms for field and industrial use. Its patented PCR.smart system combines portability, accuracy, and speed to deliver lab-quality results in agriculture, veterinary medicine, and food safety applications.

About Carlson Investments SE
Carlson Investments SE, listed on Warsaw's NewConnect and the German Open Market (Frankfurt, Munich, Stuttgart, Gettex), supports high-growth early-stage tech ventures across healthtech, AI, fintech, and deeptech. Carlson applies a hands-on investment approach and integrates its portfolio companies into a global network of strategic partnerships.

Risk Disclaimer
This announcement • does not constitute investment advice or a solicitation to buy or sell financial instruments • involves risks, including possible loss of capital • does not guarantee future earnings • past performance is not indicative of future results.

WE ARE PUBLICLY LISTED, YOU CAN BUY OUR SHARES ON:

Warsaw Stock Exchange (PLN):   CAI, PLHOTB000011
Frankfurt Stock Exchange (EUR):   2HB (FRA), PLHOTB000011
Munich Stock Exchange (EUR):   2HB (MUN), PLHOTB000011
Stuttgart Stock Exchange (EUR):   2HB (STU), PLHOTB000011
GETTEX Exchange (EUR):   2HB (GET), PLHOTB000011
WKN:   A0RNWQ

Press Contact:
Management Office
Carlson Investments SE
ir@carlsonvc.com
www.carlsonvc.com